Selective serotonin uptake inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''serotonin uptake inhibitors''' are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft. | {{subpages}} | ||
In [[medicine]], '''selective serotonin uptake inhibitors''' (SSRI) are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft. | |||
==Examples== | ==Examples== | ||
Revision as of 21:22, 21 August 2010
In medicine, selective serotonin uptake inhibitors (SSRI) are second-generation antidepressants that potentiate the effect of serotonin by blocking its uptake from the synaptic cleft.
Examples
- Citalopram (generic). Can be combined with bupropion.
- Duloxetine. Inhibits cytochrome P-450 CYP2D6.
- Fluoxetine (generic). Inhibits cytochrome P-450 CYP2D6.
- Paroxetine (generic). Inhibits cytochrome P-450 CYP2D6. May increase death from breast cancer among women taking tamoxifen due to inhibiting metabolism of tamoxifen to itc active metabolite by cytochrome P-450 CYP2D6.[1]
- Sertraline (generic)
References
- ↑ Kelly, Catherine M; David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat (2010-02-08). "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340 (feb08_1): c693. DOI:10.1136/bmj.c693. Retrieved on 2010-02-10. Research Blogging.